Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The ...

TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

Trodelvy is for adults with triple-negative breast cancer (TNBC) or hormone receptor (HR)-positive, HER2-negative breast cancer (HR+/HER2-) that has spread in the body or cannot be removed by surgery.

Trodelvy (sacituzumab govitecan-hziy) is a prescription infusion that treats certain forms of breast cancer in adults. Learn about dosage, side effects, and more.

TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

Trodelvy is a first-in-class Trop-2-directed antibody-drug conjugate. The ASCENT-03 study is a global, open-label, randomized phase III trial evaluating the efficacy and safety of Trodelvy ...

Trodelvy is a prescription drug used to treat certain types of cancer. Learn about its common, mild, and serious side effects and how to manage them.

Trodelvy is a prescription drug used to treat certain breast and bladder cancers. Learn about the drug's uses, success rate, effectiveness, and more.

Trodelvy significantly reduced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard single-agent chemotherapy Trodelvy is the ...

Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale. Gilead needs Arcellx more than ever.

May 31 (Reuters) - Gilead Sciences' , opens new tab Trodelvy in combination with Merck's , opens new tab blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer ...

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer ...